Buck Institute for Research on Aging
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
Well documented through NIH grant records, peer-reviewed publications including a landmark Science paper, and independent journalism; its research is generally regarded as mainstream geroscience, though translational outcomes such as the Unity Biotechnology senolytic trial have had mixed clinical results.
Reference only. Not medical advice.
The Buck Institute for Research on Aging conducts basic and translational research into the biological mechanisms of aging, operating as an independent, NIH-affiliated nonprofit rather than a university department. Its scientific programs span cellular senescence, mitochondrial function, stem cell biology, neurodegeneration, cancer, metabolism, and more recently AI-assisted computational biology, with the shared premise that aging itself, rather than any single disease, is the primary driver of chronic illness in later life and can potentially be targeted directly. The institute's roughly 65 million dollar annual budget as of the mid-2020s draws a little over half from NIH grants, about a third from philanthropic donors and foundations, and a smaller share from the Buck Trust endowment, supplemented by state funding including a California Institute for Regenerative Medicine award that helped build a 2012 research building. In 2000 Buck researchers published a study in Science demonstrating that a drug-like compound could extend lifespan in an animal model, an early landmark for pharmacological approaches to aging. In 2007 the institute helped establish geroscience as a distinct research field, and in 2014 it co-founded, with the University of Southern California, the first PhD program in the biology of aging in the United States. Research from the laboratory of Buck faculty member Judith Campisi on cellular senescence underpinned the 2011 founding of Unity Biotechnology, which in June 2018 dosed the first human patient in a clinical trial of a senolytic drug intended to clear senescent cells in osteoarthritis, the first such trial for this drug class; that particular candidate was later discontinued after disappointing Phase II results, illustrating both the institute's role in translating aging biology into clinical programs and the field's high early-stage failure rate. The Buck Institute is generally regarded as a credible, mainstream node in geroscience, distinguished by heavy NIH grant funding, peer-reviewed publication in leading journals, and direct academic and training partnerships with universities, while its most speculative work, like elsewhere in the field, still awaits clinical validation in humans.
The Buck Institute for Research on Aging conducts basic and translational research into the biological mechanisms of aging, operating as an independent.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
Established in 1999 in Novato, California, funded by the estate of Marin County philanthropists Leonard and Beryl Hamilton Buck, whose trust provides a share of net income to the institute in perpetuity. Harvard gerontologist John W. Rowe convened the founding scientific plan, and the campus itself was designed by architect I. M. Pei. It was created explicitly as the first independent biomedical research institute in the world devoted solely to the biology of aging, a focus it has kept for over two decades while broadening into cancer, neurodegeneration, and computational biology as those fields intersected with aging research.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Buck Institute for Research on Aging. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
- Where we land. We have not taken a position on this yet.
- What people take it for. We have not catalogued the claims made for it.